Trial reportJournal of pain and symptom management2023
Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer.
Trial report in Journal of pain and symptom management, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Effect of a Symptom Surveillance and Collaborative Care Intervention on Palliative Care Utilization.Journal of pain and symptom management · 2026Trial
- Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical Trial.JAMA network open · 2026Observational
- Social wellbeing, loneliness, and symptom burden in head and neck cancer survivors: a latent class analysis.Journal of psychosocial oncology · 2026Article
- From reporting to relating: Reimagining ePROMs in cancer symptom management.Social science & medicine (1982) · 2026Article
- Patient health engagement as a predictor of symptom outcomes in patients receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Symptom experience and management in patients with differentiated thyroid cancer during initial treatment: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Health fitness, physical activity, and quality of life in patients undergoing first chemotherapy for lung cancer: a cross-sectional study.Scientific reports · 2025Article
- Using Electronic Health Records to Classify Cancer Site and Metastasis.Applied clinical informatics · 2025Article
- Prognostic impact of patient-reported symptoms in multiple myeloma.Blood advances · 2025Article
- Article
- Latent class analysis of depression among patients with non-small cell lung cancer after surgery: A cross-sectional study.PloS one · 2025Article
- Predictors of Concordance between Patient-Reported and Provider-Documented Symptoms in the Context of Cancer and Multimorbidity.Applied clinical informatics · 2024Article
- The role of spirituality in pain experiences among adults with cancer: an explanatory sequential mixed methods study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Factors influencing self-regulatory fatigue in patients undergoing chemotherapy for gynecologic cancer: a cross-sectional study.Frontiers in psychiatry · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo examine the prevalence, severity, and co-occurrence of SPPADE symptoms as well as their association with cancer type and patient characteristics.
backgroundThe SPPADE symptoms (sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy /fatigue) are prevalent, co-occurring, and undertreated in oncology and other clinical populations.
methodsBaseline SPPADE symptom data were analyzed from the E2C2 study, a stepped wedge pragmatic, population-level, cluster randomized clinical trial designed to evaluate a guideline-informed symptom management model targeting the six SPPADE symptoms. Symptom prevalence and severity were measured with a 0-10 numeric rating (NRS) scale for each of the six symptoms. Prevalence of severe (NRS ≥ 7) and potential clinically relevant (NRS ≥ 5) symptoms as well as co-occurrence of clinical symptoms were determined. Distribution-based methods were used to estimate the minimally important difference (MID). Associations of cancer type and patient characteristics with a SPPADE composite score were analyzed.
resultsA total of 31,886 patients were assessed for SPPADE symptoms prior to, during, or soon after an outpatient medical oncology encounter. The proportion of patients with a potential clinically relevant symptom ranged from 17.5% for depression to 33.4% for fatigue. Co-occurrence of symptoms was high, with the proportion of patients with three or more additional clinically relevant symptoms ranging from 45.2% for fatigue to 68.6% for depression. The summed SPPADE composite score demonstrated good internal reliability (Cronbach's alpha of 0.86), with preliminary MID estimates of 4.1-4.3. Symptom burden differed across several types of cancer but was generally similar across most sociodemographic characteristics.
conclusionThe high prevalence and co-occurrence of SPPADE symptoms in patients with all types of cancer warrants clinical approaches that optimize detection and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.